1st Jul 2014 10:55
For immediate release | 1 July 2014 |
Oxford BioMedica plc Director's Share Purchase
Oxford, UK - 1 July 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 30 June 2014 that one of its Directors has acquired ordinary shares of 1p each ("Ordinary Shares") as follows:
|
|
|
| Interest after purchase | |
Director / PDMR | Title | Price per share (p) | Number of Ordinary Shares acquired on 30 June 2014 | Number of Ordinary Shares | % of total issued share capital |
Paul Blake | Non-Executive Director | 2.85 | 285,000 | 2,068,097 | 0.083% |
The issued share capital of the Company is 2,494,584,919 1p ordinary shares.
-Ends-
For further information, please contact: |
| |
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer |
Tel: +44 (0)1865 783 000 | |
|
| |
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications | Tel: +44 (0)20 3709 5700 | |
Notes to editors
Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Related Shares:
Oxford Biomedica